Breaking Finance News

Jefferies International disclosed GlaxoSmithKline PLC (LON:GSK), supporting its stock price target at 2,000.00GBX earlier today

Jefferies International held the target stock price of GlaxoSmithKline PLC (LON:GSK) at 2,000GBX, stating a possible upside of 0.19%.

Previously on 8/03/2016, UBS released a statement for GlaxoSmithKline PLC(LON:GSK) raised the target price from 1,420.00GBX to 1,650.00GBX. At the time, this indicated a possible downside of -0.01%.

Just yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.49% lower at 1,678.75GBX. GlaxoSmithKline PLC’s 50-day moving average is 1,658.43GBX and its two hundred day average is 1,524.87GBX. The last close is up 5.98% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. Volume of trade was was up over the average, with 13,339,146 shares of GSK changing hands over the typical 8,806,050 shares..

Recent Performance Graphic:

GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline PLC has a P/E of 2,693 with a 52 week low of 1,227.50GBX and a 52 week high of 1,716.50GBX and has a total market value of 0.0 GBX.

A total of 24 analysts have issued a ratings update on the company. Three analysts rate the stock a strong buy, six firms rate the stock a buy, 17 analyts rate the company a hold, two firms rate the stock to underperform, and lastly 0 firmsrate the stock as sell with a one year target of 1,577.33GBX

Brief Synopsis On GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.